KIMS schedules analyst meets from May 25
Krishna Institute of Medical Sciences Limited has scheduled analyst and institutional investor meetings from May 25, 2026 to May 29, 2026, via calls, video conferences, and in-person sessions. The company stated that discussions will rely on public business outlook information and no unpublished price sensitive information will be shared.
*this image is generated using AI for illustrative purposes only.
Krishna Institute of Medical Sciences Limited has informed the stock exchanges about a series of meetings with analysts and institutional investors. These interactions are scheduled to be conducted between May 25, 2026 and May 29, 2026. The meetings will be held through various modes including one-on-one calls, group video conferences, and in-person sessions.
The company confirmed that the discussions during these meetings will be based on the general business outlook and information already available in the public domain. Krishna Institute of Medical Sciences Limited emphasized that no unpublished price sensitive information (UPSI) will be disclosed during these interactions. This measure ensures compliance with regulatory standards regarding fair disclosure.
The schedule for the meetings is subject to potential changes due to exigencies on the part of the investors or the company. This intimation was made pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
| Meeting Details | Particulars |
|---|---|
| Event | Analyst/Institutional Investor Meetings |
| Start Date | May 25, 2026 |
| End Date | May 29, 2026 |
| Modes | Calls, Video Conference, In-person |
| Disclosure Policy | No UPSI to be shared |
Historical Stock Returns for Krishna Institute of Medical Sciences
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +1.45% | +7.10% | +17.90% | +13.72% | +14.44% | +285.05% |
How might the insights shared during these analyst meetings influence institutional investor sentiment and KIMS stock performance in the near term?
What key financial metrics or expansion plans is KIMS likely to highlight given the current competitive landscape of the Indian healthcare sector?
Could increased analyst coverage following these roadshows potentially lead to revised earnings estimates or target price upgrades for KIMS?
20
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
